.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Colorcon
Chubb
Express Scripts
Covington
Teva
Fish and Richardson
Chinese Patent Office
McKesson
Julphar

Generated: December 18, 2017

DrugPatentWatch Database Preview

Wyeth Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for WYETH PHARMS INC, and what generic alternatives to WYETH PHARMS INC drugs are available?

WYETH PHARMS INC has thirty-one approved drugs.

There are eighteen US patents protecting WYETH PHARMS INC drugs on WYETH PHARMS INC drugs in the past three years.

There are three hundred and ten patent family members on WYETH PHARMS INC drugs in sixty-four countries and twenty-five supplementary protection certificates in ten countries.

Summary for Wyeth Pharms Inc

International Patents:310
US Patents:18
Tradenames:29
Ingredients:19
NDAs:31
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms IncZOSYNpiperacillin sodium; tazobactam sodiumINJECTABLE;INJECTION050684-001Oct 22, 1993APRXYesYes► Subscribe► SubscribeY► Subscribe
Wyeth Pharms IncPIPRACILpiperacillin sodiumINJECTABLE;INJECTION062750-003Oct 13, 1987DISCNNoNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms IncPREMARINestrogens, conjugatedCREAM;TOPICAL, VAGINAL020216-001Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe► Subscribe
Wyeth Pharms IncLODINEetodolacTABLET;ORAL018922-005Jun 28, 1996DISCNYesNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms IncPHOSPHOLINE IODIDEechothiophate iodideFOR SOLUTION;OPHTHALMIC011963-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms IncZOSYN IN PLASTIC CONTAINERpiperacillin sodium; tazobactam sodiumINJECTABLE;INJECTION050750-002Feb 24, 1998RXYesYes► Subscribe► SubscribeY► Subscribe
Wyeth Pharms IncPREMPROestrogens, conjugated; medroxyprogesterone acetateTABLET;ORAL-28020527-005Jun 4, 2003RXYesYes► Subscribe► Subscribe► Subscribe
Wyeth Pharms IncLODINE XLetodolacTABLET, EXTENDED RELEASE;ORAL020584-002Oct 25, 1996DISCNYesNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms IncPREMPROestrogens, conjugated; medroxyprogesterone acetateTABLET;ORAL-28020527-001Nov 17, 1995RXYesYes► Subscribe► Subscribe► Subscribe
Wyeth Pharms IncZOSYNpiperacillin sodium; tazobactam sodiumINJECTABLE;INJECTION050684-003Oct 22, 1993APRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Wyeth Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms IncMYLOTARGgemtuzumab ozogamicinINJECTABLE;INJECTION021174-001May 17, 2000► Subscribe► Subscribe
Wyeth Pharms IncPREMARINestrogens, conjugatedTABLET;ORAL004782-004Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Wyeth Pharms IncEFFEXOR XRvenlafaxine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL020699-003Oct 20, 1997► Subscribe► Subscribe
Wyeth Pharms IncEFFEXOR XRvenlafaxine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL020699-002Oct 20, 1997► Subscribe► Subscribe
Wyeth Pharms IncMYLOTARGgemtuzumab ozogamicinINJECTABLE;INJECTION021174-001May 17, 2000► Subscribe► Subscribe
Wyeth Pharms IncEFFEXOR XRvenlafaxine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL020699-003Oct 20, 1997► Subscribe► Subscribe
Wyeth Pharms IncEFFEXOR XRvenlafaxine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL020699-003Oct 20, 1997► Subscribe► Subscribe
Wyeth Pharms IncLODINEetodolacCAPSULE;ORAL018922-002Jan 31, 1991► Subscribe► Subscribe
Wyeth Pharms IncMYLOTARGgemtuzumab ozogamicinINJECTABLE;INJECTION021174-001May 17, 2000► Subscribe► Subscribe
Wyeth Pharms IncPREMPROestrogens, conjugated; medroxyprogesterone acetateTABLET;ORAL-28020527-001Nov 17, 1995► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for WYETH PHARMS INC drugs

Drugname Dosage Strength Tradename Submissiondate
desvenlafaxine succinate Extended-release Tablets 25 mg PRISTIQ 5/8/2015
desvenlafaxine succinateExtended-release Tablets50 mg and 100 mgPRISTIQ2/29/2012
piperacillin sodium and tazobactam sodiumFor Injection12 g/1.5 g per vial (pharmacy bulk)ZOSYN12/6/2011
levonorgestrel and ethinyl estradiolTablets0.09 mg/0.02 mgLYBREL10/5/2007
venlafaxine hydrochlorideExtended-release Tablets37.5 mg, 75 mg and 150 mgEFFEXOR XR5/3/2007
venlafaxine hydrochlorideTablets25 mg, 37.5 mg, 50 mg, 75 mg and 100 mgEFFEXOR11/3/2005
pantoprazole sodiumDelayed-release Tablets20 mg and 40 mgPROTONIX2/2/2004

Non-Orange Book Patents for Wyeth Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,026,508Succinate salt of O-desmethyl-venlafaxine► Subscribe
7,498,312Compositions containing piperacillin and tazobactam useful for injection► Subscribe
7,291,347Succinate salt of O-desmethyl-venlafaxine► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Wyeth Pharms Inc Drugs

Country Document Number Estimated Expiration
Israel171337► Subscribe
Portugal1468697► Subscribe
Eurasian Patent Organization011451► Subscribe
Norway303714► Subscribe
Hungary224617► Subscribe
Latvia11982► Subscribe
Hong Kong1056686► Subscribe
Denmark1468697► Subscribe
Honduras2002000030► Subscribe
Australia1140999► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Wyeth Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
323Luxembourg► SubscribePRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624
13/055Ireland► SubscribePRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
2009 00017Denmark► SubscribePRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
C0032Belgium► SubscribePRODUCT NAME: PANTOPRAZOL. NATR. SESQUIHYDRAS PANTOPRAZOLE; NAT. REGISTRATION NO/DATE: 127 IS 98 F 3 19960222; FIRST REGISTRATION: SE 12131 19940506
0443983/03Switzerland► SubscribePRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
C0030France► SubscribePRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
2006 00038Denmark► SubscribePRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
2015000093Germany► SubscribePRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
C/GB99/008United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
C0062France► SubscribePRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
US Army
Merck
Cantor Fitzgerald
Chinese Patent Office
Colorcon
Queensland Health
UBS
Cipla
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot